by John Miller | Apr 22, 2018 | BioPharma
ZURICH (Reuters) – Swiss drugmaker Roche on Friday won a key European panel’s recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators’ go-ahead earlier this year. FILE PHOTO:... 
by Tamara Mathias | Apr 22, 2018 | BioPharma
A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder (Reuters) – Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the... 
by Reuters Staff | Apr 21, 2018 | BioPharma
FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski FRANKFURT (Reuters) – Merck KGaA will seek development partners for experimental treatments including tepotinib as the German... 
by Editing by Michael Shields | Nov 9, 2017 | BioPharma, Oncology
Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann ZURICH (Reuters) – New data from Novartis’s breast cancer drug Kisqali underscored its... 
by Matthias Blamont | Oct 29, 2017 | BioPharma
VAL-DE-REUIL, France (Reuters) – Sanofi on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France. FILE PHOTO – A logo... by Sarah Buhr | Oct 29, 2017 | BioPharma
Begin: WordPress Article Content Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify 100 new treatments in 10 years. That’s a...